Paul Matteis
Stock Analyst at Stifel
(1.91)
# 3,128
Out of 4,918 analysts
110
Total ratings
38.6%
Success rate
-8.31%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Buy | $166 → $174 | $128.18 | +35.75% | 9 | Jul 31, 2025 | |
| DYN Dyne Therapeutics | Maintains: Buy | $66 → $36 | $10.20 | +252.94% | 4 | Jul 31, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $78 → $94 | $87.13 | +7.88% | 2 | May 29, 2025 | |
| VIGL Vigil Neuroscience | Downgrades: Hold | $11 → $8 | $8.04 | -0.50% | 2 | May 28, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $300 → $345 | $396.92 | -13.08% | 14 | Mar 31, 2025 | |
| NMRA Neumora Therapeutics | Downgrades: Hold | $6 → $2 | $1.68 | +19.05% | 2 | Mar 7, 2025 | |
| SION Sionna Therapeutics | Initiates: Buy | $32 | $16.75 | +91.04% | 1 | Mar 4, 2025 | |
| GHRS GH Research | Maintains: Buy | $18 → $32 | $14.07 | +127.43% | 2 | Feb 27, 2025 | |
| CMPS COMPASS Pathways | Initiates: Buy | $11 | $4.43 | +148.31% | 1 | Feb 27, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $490 → $494 | $463.42 | +6.60% | 18 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $32 | $13.92 | +129.89% | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $4 | $1.48 | +170.27% | 4 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $3.07 | +225.73% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $44 → $60 | $22.66 | +164.84% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $25 → $36 | $26.61 | +35.29% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $87 | $57.74 | +50.68% | 8 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $14.35 | +143.90% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $50 → $53 | $42.70 | +24.12% | 5 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $26 → $21 | $23.71 | -11.43% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $5.64 | +414.18% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $287 | $130.08 | +120.63% | 6 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $4.68 | +327.35% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $2.90 | +313.79% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $24 | $1.34 | +1,691.04% | 2 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $36 → $5 | $0.38 | +1,226.26% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $32 | $13.30 | +140.60% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $1.38 | +1,856.52% | 1 | Jul 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $10.94 | +27.97% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $64 | $8.52 | +651.17% | 1 | Feb 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $340 | $62.99 | +439.77% | 1 | Dec 21, 2016 |
Neurocrine Biosciences
Jul 31, 2025
Maintains: Buy
Price Target: $166 → $174
Current: $128.18
Upside: +35.75%
Dyne Therapeutics
Jul 31, 2025
Maintains: Buy
Price Target: $66 → $36
Current: $10.20
Upside: +252.94%
Rhythm Pharmaceuticals
May 29, 2025
Maintains: Buy
Price Target: $78 → $94
Current: $87.13
Upside: +7.88%
Vigil Neuroscience
May 28, 2025
Downgrades: Hold
Price Target: $11 → $8
Current: $8.04
Upside: -0.50%
Alnylam Pharmaceuticals
Mar 31, 2025
Maintains: Buy
Price Target: $300 → $345
Current: $396.92
Upside: -13.08%
Neumora Therapeutics
Mar 7, 2025
Downgrades: Hold
Price Target: $6 → $2
Current: $1.68
Upside: +19.05%
Sionna Therapeutics
Mar 4, 2025
Initiates: Buy
Price Target: $32
Current: $16.75
Upside: +91.04%
GH Research
Feb 27, 2025
Maintains: Buy
Price Target: $18 → $32
Current: $14.07
Upside: +127.43%
COMPASS Pathways
Feb 27, 2025
Initiates: Buy
Price Target: $11
Current: $4.43
Upside: +148.31%
Vertex Pharmaceuticals
Dec 16, 2024
Maintains: Hold
Price Target: $490 → $494
Current: $463.42
Upside: +6.60%
Dec 16, 2024
Maintains: Buy
Price Target: $12 → $32
Current: $13.92
Upside: +129.89%
Dec 16, 2024
Downgrades: Hold
Price Target: $4
Current: $1.48
Upside: +170.27%
Nov 13, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $3.07
Upside: +225.73%
Nov 12, 2024
Maintains: Buy
Price Target: $44 → $60
Current: $22.66
Upside: +164.84%
Nov 5, 2024
Upgrades: Buy
Price Target: $25 → $36
Current: $26.61
Upside: +35.29%
Sep 17, 2024
Maintains: Buy
Price Target: $115 → $87
Current: $57.74
Upside: +50.68%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $14.35
Upside: +143.90%
Jun 27, 2024
Maintains: Hold
Price Target: $50 → $53
Current: $42.70
Upside: +24.12%
May 9, 2024
Maintains: Hold
Price Target: $26 → $21
Current: $23.71
Upside: -11.43%
Apr 30, 2024
Initiates: Buy
Price Target: $29
Current: $5.64
Upside: +414.18%
Dec 14, 2023
Maintains: Buy
Price Target: $315 → $287
Current: $130.08
Upside: +120.63%
Nov 28, 2023
Initiates: Buy
Price Target: $20
Current: $4.68
Upside: +327.35%
Nov 14, 2023
Initiates: Buy
Price Target: $12
Current: $2.90
Upside: +313.79%
Jun 14, 2023
Reiterates: Buy
Price Target: $24
Current: $1.34
Upside: +1,691.04%
Jun 23, 2022
Downgrades: Hold
Price Target: $36 → $5
Current: $0.38
Upside: +1,226.26%
Jun 8, 2022
Maintains: Buy
Price Target: $54 → $32
Current: $13.30
Upside: +140.60%
Jul 26, 2021
Initiates: Buy
Price Target: $27
Current: $1.38
Upside: +1,856.52%
Mar 12, 2020
Initiates: Buy
Price Target: $14
Current: $10.94
Upside: +27.97%
Feb 21, 2018
Maintains: Outperform
Price Target: $53 → $64
Current: $8.52
Upside: +651.17%
Dec 21, 2016
Initiates: Outperform
Price Target: $340
Current: $62.99
Upside: +439.77%